Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

[1]  A. Y. Lu,et al.  Pharmacogenomics and Individualized Medicine , 2012 .

[2]  B. J. Klevering,et al.  Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. , 2012, Ophthalmology.

[3]  Geoffrey S Ginsburg,et al.  Personalized medicine: progress and promise. , 2011, Annual review of genomics and human genetics.

[4]  W. Berger,et al.  Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.

[5]  A. Y. Lu,et al.  Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.

[6]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[7]  M. McKibbin,et al.  CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration , 2011, British Journal of Ophthalmology.

[8]  A. Negi,et al.  The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy , 2011, Molecular vision.

[9]  P. Rosenfeld,et al.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.

[10]  S. Teper,et al.  Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration , 2010, Molecular vision.

[11]  P. Charbel Issa,et al.  The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  S. Michels,et al.  Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders. , 2010, Klinische Monatsblatter fur Augenheilkunde.

[13]  P. Tommila,et al.  Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.

[14]  Ivana K. Kim,et al.  Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. , 2009, American journal of ophthalmology.

[15]  G. Gilkeson,et al.  A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. , 2009, Investigative ophthalmology & visual science.

[16]  M. Brantley,et al.  Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab , 2008, British Journal of Ophthalmology.

[17]  S. Wolf.  Current status of anti-vascular endothelial growth factor therapy in Europe , 2008, Japanese Journal of Ophthalmology.

[18]  Martin Oppermann,et al.  Systemic Complement Activation in Age-Related Macular Degeneration , 2008, PloS one.

[19]  E. Souied,et al.  Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes. , 2008, Investigative ophthalmology & visual science.

[20]  P. Tommila,et al.  Complement factor H Y402H polymorphism and characteristics of exudative age‐related macular degeneration lesions , 2008, Acta ophthalmologica.

[21]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[22]  B. Rosner,et al.  Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. , 2007, JAMA.

[23]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[24]  John D Lambris,et al.  Drusen complement components C3a and C5a promote choroidal neovascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Dugel.  Ranibizumab Treatment of Patients With Ocular Diseases , 2006, International ophthalmology clinics.

[26]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[27]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[28]  J. Haines,et al.  Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. , 2004, American journal of human genetics.

[29]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[30]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[31]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[32]  P. Harden,et al.  Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.

[33]  J. Slakter,et al.  RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.

[34]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[35]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[36]  D. Eliott,et al.  Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.

[37]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[38]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.